

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/805,455
Filing Date	March 14, 2001
First Named Inventor	Weiniu GAN et al.
Art Unit	1634
Examiner Name	J. Fredman
Attorney Docket Number	CL001165

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
✓		WO 98 53601 A1	11/26/1998	Council of Queensland...		

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	09/805,455
Filing Date	March 14, 2001
First Named Inventor	Weiniu GAN et al.
Group Art Unit	1634
Examiner Name	J. Fredman
Attorney Docket Number	CL001165

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		Kawasaki et al. "A Rap Guanine Nucleotide Exchange Factor Enriched Highly in Basal Ganglia." Proc. Natl. Acad. Sci. October 1998. Vol. 95, Pages 13278-13283.	
✓		Clyde-Smith et al. "Characterization of RasGRP2, a Plasma Membrane-Targeted Dual Specifically Ras/Rap Exchange Factor." J. Biol. Chem. October 13, 2000. Vol. 275, No. 41, Pages 32260-32267.	
✓		Kedra et al. "The Germinal Center Kinase Gene and a Novel CDC-25 Like Gene are Located in the Vicinity of the PYGM Gene on 11q13." Human Genet. 1997. Vol. 100, Pages 611-619.	
✓		Guru et al. "A Transcript Map for the 2.8 Mb Region Containing the Multiple Endocrine Neoplasia Type 1 Locus." Genome Research. 1997. Vol. 7, Pages 725-735.	
		International Search report dated May 22, 2003.	

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**